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Severe consequences of mother-to-child transmission of syphilis and high increasing incidence of 
congenital syphilis remains an important public health problem in Brazil.  
Objectives 
To assess cost-effectiveness of a rapid point-of-care test (RT) and treatment of positive mothers 
immediately compared to laboratory-based standard test (ST) with treatment at next follow-up 
visit. 
Methods 
Decision analytic model was developed to estimate the incremental cost effectiveness ratio (ICER) 
between antenatal syphilis screening strategies. Model was built with lifetime horizon from 
Brazilian health system perspective using 3% and 5% discount rate. A hypothetical cohort of 
pregnant women at reproductive age enter the model. Health outcomes: low birth weight, 
stillbirths, neonatal deaths and congenital syphilis were estimated in Disability-Adjusted Life 
Years (DALYs) lost. Micro-costing study and secondary data provided parameters of direct 
medical costs.  Probabilistic sensitivity analysis was undertook. 
Results 
For base-case, the mean cost per pregnant woman screened was US$2.63 (RT) and US$2.48 (ST), 
respectively. Maternal syphilis was associated with a loss of 0.0043 DALYs(RT) and 0.0048 
DALYs(ST) per mother screened. Expected value of incremental cost per DALY averted was 
US$298.08. After 10000 PSA model runs, incremental cost and health benefits were US$0.15 
(95%CrI -1.56- 1.92) and 0.00042 DALYs (95%CrI -0.0036-0.0044) respectively, mean ICER of 
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US$357.44 per DALY. Screening with RT has a 58% chance of being the optimal strategy at a 
threshold of US$3,200 per DALY.  
Conclusions 
In Brazil, antenatal screening with syphilis RT and immediate treatment is likely to be cost-
effective compared to standard screening and must be prioritized in local settings. 
Keywords: syphilis screening, maternal syphilis, pregnant women, rapid test, cost-effectiveness 
Highlights 
 Latin-American countries had been doing relevant efforts in the control of sexually transmitted 
diseases and particularly for elimination of mother-to-child syphilis transmission. Economic 
study on the cost-effectiveness of screening gestational syphilis with rapid diagnostic tests 
during prenatal care has absolute relevance for the country, considering the severe 
consequences of mother-to-child transmission of the disease and the high incidence of 
congenital syphilis in Brazil. 
 We show that syphilis screening in pregnancy with rapid test and treatment of positives in the 
same day of antenatal visit is likely to be a highly cost-effective strategy in Brazil. This is 
significant because despite the free access to treatment by pregnant women in the Unified 
Health System (SUS) and the increased diagnosis and improved access to prenatal care, the 
number of new cases of syphilis in pregnancy and childbirth have been increasing in recent 
last years. 
 Economic evaluation could help the Ministry of Health decision makers in setting the future 
directions for the syphilis mother-to-child transmission strategy and provide a better 
understanding of new testing technologies. Our findings indicate that strategies including rapid 
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tests for syphilis should be reinforced and prioritized in local settings and could be extended to 
other low- and middle-income countries. 
 
1. Introduction 
Latin-American countries account for up to 25% of the 2 million annual cases of gestational 
syphilis. Annually, an estimated 100000 stillbirths in the region are attributable to congenital 
syphilis. The prevalence of gestational syphilis in Latin-American countries varies from 0.08% to 
7.0% by country (1). In Brazil, the rate of detection of gestational syphilis and incidence rate of 
congenital syphilis has increased since 2010, reaching  8.6 reported cases/1000 live births in 2017 
(2). The benefits of preventing congenital syphilis through antenatal screening have been 
demonstrated in the literature (3,4). The advent of rapid testing has brought the possibility of 
faster treatment with improved compliance. However, it is still paramount to establish the cost-
effectiveness of different screening strategies within country-specific contexts. 
To date, the conventional approach to testing recommended by the World Health Organization 
(WHO) has been an algorithm of nontreponemal test (NTT), such as the Venereal Diseases 
Research Laboratory test (VDRL) in combination with a treponemal test (TT) such as Treponema 
Pallidum Hemagglutination Assay (TPHA) (5). Whilst VDRL+TPHA testing provides high 
sensitivity and specificity, the necessary delay in generating results means that women identified 
as positive are treated only in the next visit with some consequent loss to follow-up. Rapid tests in 
comparison allow presumptive diagnostics and the possibility of immediate treatment. Whilst 
there is some evidence that RT may have a similar sensitivity and higher specificity than 
conventional testing, it may not differentiate between past and current infection (6–10). 
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Despite the existing evidence of the cost-effectiveness of rapid syphilis tests in antenatal screening 
programmes (11,12), most studies were undertaken in African countries with few in South 
America or the Caribbean Region. Studies conducted in Brazil focus on assessing the diagnostic 
performance, usefulness and costs of a rapid treponemal antibody assay to detect syphilis in high-
risk populations (13–15), with no evidence concerning cost-effectiveness. The Brazilian program 
for reducing morbidity and mortality from gestational and congenital syphilis (16) has gradually 
been adopting tracking techniques through rapid tests for early detection of cases and abandoning 
the conventional reference test (17). The aim of this change is to bring about increased uptake of 
syphilis testing, increased treatment rates and reduction in adverse pregnancy outcomes such as 
low birth weight or prematurity, stillbirths or miscarriage, neonatal deaths and congenital syphilis. 
This study was nested in the Project Evaluation of Strategies for Tracking Dengue and Syphilis in 
Primary Care sponsored by the Department of Science and Technology of Brazilian Ministry of 
Health developed in 2015, with the objective to bring responses about the gradual implementation 
of rapid testing in the program of antenatal screening in public health units along the country. The 
relevance of this issue for health policy is because despite the free access to treatment by pregnant 
women in the Unified Health System (SUS) and the increased diagnosis and improved access to 
prenatal care, the number of new cases of syphilis in pregnancy and childbirth have been 
increasing in recent years. 
The goal of this study was to build a decision analytic model to compare the cost-effectiveness of 
rapid versus conventional syphilis screening strategies at antenatal care sites to prevent mother-to-
child syphilis transmission and to avert adverse birth outcomes in Brazil. Two antenatal syphilis 
screening strategies were compared, performing a rapid test (Immunochromatographic Syphilis, 
ICS) on-site with same-day treatment versus the standard reference test (VDRL+TPHA) 




2. Materials and Methods 
Population 
The population is a hypothetical cohort of all pregnant women who receive antenatal care and are 
at risk of sexual transmitted infection, specifically syphilis. This includes in Brazil, sexual active 
women between 10 and older than 49 years old (reproductive age in Brazil) (18). 
Setting and location 
There is a Brazilian program for reducing morbidity and mortality from gestational syphilis and 
congenital syphilis (16) considering early diagnosis and treatment one of the most effective 
strategies of syphilis control at antenatal care sites for pregnant women screening. 
Study perspective and time horizon 
We adopted the public health system perspective. A lifetime horizon was used in order to capture 
the full potential health impact of antenatal syphilis screening and to enable budgetary 
consequences in primary care sites to be estimated. Effects and costs were discounted at 3% and 
5%. 
Prevalence 
Prevalence of syphilis was estimated at 1.2% (95%CI 0.98-1.47) of women in pregnancy based on 
a large hospital-based cohort study considering only the births that occurred in public health care 
units (19). 
Comparators 
Antenatal syphilis screening strategies were compared, performing a rapid test 
(Immunochromatographic Syphilis, ICS) on-site with same-day treatment versus the standard 
reference test (VDRL+TPHA) performed off-site with treatment at follow-up visit. 
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RTs have been shown to have good sensitivity, median of 0.86 (IQR 0.75, 0.94) and high 
specificity, median of 0.99 (IQR 0.98, 0.99) according to the systematic review by Tucker et al 
(9).  
Recently, another study found pooled sensitivity and specificity of 0.85 (95%CI 0.73, 0.92) and 
0.98 (95%CI: 0.95, 0.99) respectively (10). These values were used in the model. Despite its high 
specificity, RT is unable to distinguish between past and active syphilis. 
The ST comprising NTT (VDRL) and TT (TPHA) provides a sensitivity of 0.88% (0.78, 1.00) and 
specificity of 0.98 (0.98, 1.00) (6,20,21). 
Health Outcomes 
The focus of antenatal syphilis screening is on eliminating mother-to-child syphilis transmission, 
therefore the model focuses on outcomes for the baby and does not include maternal outcomes 
(22). The adverse birth outcomes included are stillbirth (i.e. foetal loss or miscarriage), low birth 
weight and prematurity, neonatal death and live born with syphilis. Live births with syphilis 
include both asymptomatic and symptomatic newborns. We do not include conditions associated 
with syphilis, such as Human immunodeficiency virus infection and acquired immune deficiency 
syndrome (HIV/AIDS). 
Efficacy of Treatment 
Penicillin G has been found to be effective in eradicating syphilis of all clinical stages as well as 
congenital infection (23). A single dose of long-acting benzathine penicillin G (2.4 million units 
i.m.) will cure a person who has primary, secondary or early latent syphilis (24,25) and three doses 
at weekly intervals is recommended for individuals with late latent syphilis or latent syphilis of 
unknown duration (24). 
Benzathine penicillin is associated with a very low risk of adverse complications. Literature 
suggests approximately 6% or 5–10% of pregnant women with syphilis report a history of 
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penicillin allergy (25,26). According to CDC (24) and adopted in Brazil (17), pregnant women 
who have a history of penicillin allergy should be desensitized and treated with penicillin. 
Penicillin allergy was not included separately in the model. 
Measurement of Effectiveness  
Utility values were estimated in terms of DALYs (Disability-adjusted life years) lost, defined as 
the sum of years of life lost due to premature mortality and years lived with disability adjusted for 
severity (27). The DALYs for adverse outcomes averted were estimated from a single study (28) 
that presented data for 43 countries in sub-Saharan Africa (SSA) adjusted for undiscounted local 
life expectancy, the neonatal standard loss function and relevant disability weights.  A full 
systematic review was not undertaken to identify this evidence, however, the study was identified 
using published principles for 
searching and choosing the best available evidence for modelling (29). Additionally, we adjusted 
the data to the mean expectancy life in Brazil (75 years in 2015). 
Modelling vertical syphilis transmission 
A literature review published by Gomez et al (30) estimated that adverse birth outcomes were 
observed in 66.5% (95%CI 53.4, 81.8) of the women with untreated syphilis. Similarly, Shahrook 
et al (31) showed that about 69% of pregnant women with active infection might experience 
adverse birth outcomes. The probabilities related to status of infection associated with model 
health outcomes, low birth weight, stillbirths, neonatal deaths and congenital syphilis are listed in 
Table 1. 
Measurement of Costs 
Direct medical costs were captured for costs of tests (RT, ST), value of personnel time, treatments 
(mother and child) and inpatient care (congenital syphilis). Direct non-medical costs or indirect 
costs were not included. 
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A micro-costing study was conducted to estimate the resource utilization associated with each 
screening strategy (RT, ST) and follow up of women treated, treatment of maternal syphilis and 
inpatient costs of congenital syphilis based on  national data available. Costs were expressed in 
Brazilian Real (BRL), only for secondary data, they were inflated to 2015 BRL using the Brazilian 
Central Bank’s cumulative inflation rate for the period between the date of each cost’s source and 
2015. Finally, all costs were converted to dollars with purchasing power parity (PPP) using the 
World Bank´s conversion factor. Costing procedures were in accordance with previously 
published methods (33). 
The total cost of testing (US$) based on reagents and labour were estimated:  
Ctesting = CA+CB 
A; Reagents= unit cost of tests  
B; Labor= cost estimated based on time used to perform the test by professional or technician  
Unit costs of tests were provided by the Drug Logistics Management and Strategic Inputs of DST 
Diseases, AIDS and Viral Hepatitis from Health Surveillance Secretariat of Ministry of Health.  
Salaries for nurses and laboratory technicians were national mean values. Time labour to perform 
testing was set up on 20 min of nurse's labour (RT) and 45 min of laboratory technician's labour 
(ST) took from literature (32) and expert opinion.  
The follow-up to assess treatment outcomes and potential re-infection involves a nontreponemal 
qualitative and quantitative test (VDRL) every month after starting the treatment. This cost was 
also accounted for pregnant women with RT positive at the first visit. The costs [Cfollow-up] are 
estimated by: 
 Cfollow-up = (Ctesting*n) 
n = number of visits that pregnant women have the opportunity to take a monitoring test. 
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An expert opinion was consulted to estimate the mean number of visits pregnant women 
accomplish to monitor treatment, seeking to bring us closer to real life data, n=3 was included in 
the model. 
The cost of treating gestational syphilis to avoid disease progression and/or vertical transmission 
is estimated by, 
[CGestationalS]= Ctesting+Ctreat+Cfollow-up 
Unit costs of penicillin to treat maternal and congenital syphilis were provided by Health Logistics 
Department from Ministry of Health (governmental purchasing system, 
https://www.comprasgovernamentais.gov.br/) and inpatient costs estimated from Table of 
Procedures, Drugs, Orthotics and Prostheses and Special Materials (OPM) of the Unified Health 
System – SUS (Management system, http://sigtap.datasus.gov.br/tabela-
unificada/app/sec/inicio.jsp). 
The unit treatment and follow up costs are the same for both testing strategies (RT, ST) but the 
total cost depends on the probabilities of treatment compliance, which differ for the two strategies. 
Total cost of a congenital syphilis case does not take into account the appointment cost because it 
is part of routine neonatal care, either for testing, treatment and follow up. 
All costs in 2015 US international dollars (USD), year when the study was carried on are listed in 
Table 2. 
General Model 
Pregnant women with access to prenatal care are evaluated for syphilis at the first antenatal visit 
(usually during 1st or 2nd trimester). A second test is also performed at 3rd trimester in those with a 
negative result at first testing (5). 
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Depending on the syphilis screening strategy, women are informed of the result and initiate 
treatment either, immediately which we term the rapid test (RT) or at the next follow-up visit, 
which represents the standard test (ST).  
In either of the strategies, if a patient is tested positive, a nontreponemal test must be performed 
monthly to assess treatment outcomes and identify failures due to non-treatment, incomplete or 
inadequate treatment or re-infection.  
The comparative strategies are in accordance with the norms of the Brazilian Low Risk Prenatal 
Care Program(17). 
Analytic Model Overview  
The model incorporates three steps of antenatal care: syphilis testing, treatment prescription and 
treatment adherence. 
Pregnant women enter the model by being tested for syphilis. Women have two possible starting 
states: infected or uninfected. The proportion of infected women was represented by national data 
on syphilis prevalence (34). For uninfected women, the probability of acquiring syphilis during 
pregnancy was represented by the primary and secondary syphilis incidence rates (34). They could 
either be tested with RT and receive same day treatment if indicated or receive the ST and be 
treated during the follow-up visit. Screening is performed in all pregnant women at least once, at 
first antenatal care visit and at third trimester of pregnancy for women negative at first testing. 
Prescription of benzathine penicillin G is based on the test result and clinical evaluation. 
Test results are modelled using the sensitivity and specificity for the appropriate test (RT vs. ST). 
Additional tests are performed (monthly) to confirm treatment success. Women with High Titre 
Active Syphilis (VDRL>1:8 and TPHA positive) receive the administration of new treatment with 
benzathine penicillin G. 
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Health outcomes depend on whether the mother fully complies with treatment and include 
stillbirth or miscarriage, low birth weight or prematurity, neonatal death, live born with syphilis, 
or an infant without congenital syphilis. Cost-effectiveness ratios were estimated in 2015 USD 
international dollars/ DALY.  
The decision analytic model was built and programmed using DATA Pro Healthcare (TreeAge 
Software, http://www.treeage.com) (Figure 1). Monte Carlo methods with 10,000 replicates were 
used to estimate economic outcomes. 
Key assumptions of model 
o Pregnant women with maternal syphilis were modelled at primary, secondary or early latent 
syphilis stage of disease (44.1%) based on national data reported and high probability of 
congenital transmission 94.0% (47.0-1.00) (12) 
o New infections occurring between the first and second test were modelled as incident 
infections based on the study of Cerda et al (21). 
o Single dose treatment is used for primary, secondary or early latent syphilis.  
o Incomplete treatment is considered to have the same efficacy as untreated cases and costs 50% 
of complete treatment. 
o If new infected or still-infected pregnant women are identified during the follow up of 
positives, they are treated. 
o The foetus receives full efficacy of therapy (97%) following a single maternal treatment. 
o Time for initiating the treatment with ST ranges between 1 week (test result available) and 4 
weeks (next follow up visit). 
o There is a probability of remission in untreated women due to antibiotic therapy with penicillin 
for infections other than syphilis. 
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o Multiple pregnancies are not included in the model. 
o Probability of re-infection due to non-treated partner is not included in the model. 
o Costs relating to training, consumables and equipment (Lab for ST) were not included in our 
model due to non-availability of data. These costs should be prorated proportionally with 
performing other laboratory testing. 
Uncertainty 
Probabilistic sensitivity analysis (PSA) was conducted and summary statistics and graphical 
illustrations are provided to illustrate the uncertainty in model outcomes. Specific 5% discount 
rate recommended by MoH was applied in the sensitivity analysis. Value of Information (VOI) 
analysis allows identification of those parameters that cause most decision uncertainty and 
estimates the potential value of reducing uncertainty by further data collection. 
Interpretation of results 
In Brazil, a cost-effectiveness threshold has not been published by government. Consequently, 
many studies have adopted WHO recommendations on the cost-effectiveness of interventions 
(35). 
Recently, cost-effectiveness thresholds based on opportunity cost were estimated for a wide range 
of low-/middle-income countries (36). Whilst their estimates relate to quality adjusted life years 
(QALYs) gained, they use DALYs and QALYs interchangeably in their paper as a summary 
measure of morbidity and mortality. The PPP-adjusted thresholds for Brazil were US$3,210-
10,122 and we have used the lowest estimated value within the analysis. 
Validation 
Validation of the conceptual model was undertaken by discussing the decision problem with 
Brazilian advisers who highlighted clinical and epidemiological aspects to be considered. A draft 
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model incorporated all comments and suggestions and a second cycle of review improved the 
development of the model. Model parameters were identified in accordance with the criteria for 
recommended minimum search requirements (29) and implementation within the model was 
verified. The model was double programmed with a parallel build in Excel in order to identify 
potential errors. 
Ethics 
Institutional and national review bodies approved the research, the Committee of Ethics in 
Research from Oswaldo Cruz Institute (IOC) from Oswaldo Cruz Foundation and the Brazilian 
National Committee of Ethics in Research (CONEP). 
 
3. Results 
Parameters definitions and values are presented in Tables 1 and 2. Test characteristics for RT and 
ST were derived from two recent systematic reviews (9,10). Literature reviews provided the 
probabilities of adverse outcomes, compliance and successful treatment (12,30,37).  Brazilian data 
were used in the model for the parameters describing prevalence of maternal syphilis (19), 
probability of new infection between tests (21) and also costs of testing and treatments. 
Additionally, the expert opinion of Brazilian advisers was used to generate values where no 
published sources were available. Statistical distributions were used to describe uncertainty in 
model parameters. Beta distributions are used for event probabilities and gamma distributions for 
cost and HRQoL parameters, a full listing of parameter values is provided in Table 3.  
The mean cost of the rapid testing strategy was estimated at US$2.63 per pregnant woman 
screened compared to a cost of US$2.48 for the standard strategy. Rapid testing was associated 
with a loss of 0.0043 DALYs compared to 0.0048 DALYs lost with standard testing. Expected 
value of incremental cost per DALY averted is US$298.08. 
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The cost-effectiveness plane (Figure 2) shows the standardized cost-effectiveness plane per person 
based on 10000 model runs in which uncertain model parameters are varied simultaneously in a 
probabilistic sensitivity analysis. The mean incremental cost of RT versus ST is US$0.15. This 
suggests that RT is more costly. The incremental cost is uncertain because the model parameters 
are uncertain. The 95% credible interval for the incremental cost ranges from US$-1.56 to 
US$1.92. The probability that RT is cost-saving compared to ST is 0.428. 
The mean incremental benefit of RT versus ST is 0.00042 DALY. Again, there is some 
uncertainty due to model parameters, with the 95% credible interval for the incremental benefit 
ranging from (-0.0036 DALY, 0.0044 DALY). The probability that RT is more beneficial than ST 
is 0.595. 
The incremental expected cost per unit of benefit is estimated at US$357.44 per DALY with 3% 
discount rate.. The Cost-Effectiveness Acceptability Curve presented in Figure 3 shows that at a 
threshold value for cost-effectiveness of US$3200 per DALY, the strategy with the highest 
probability of being most cost-effective is RT, 58.42 %. Sensitivity analysis of 5% discount rate 
estimates the ICER of US$342.29 per DALY with the highest probability of RT strategy being 
most cost-effective is 58.41%. The mean incremental cost per person is US$0.035 and the mean 
incremental effect per person is 1e-04 DALY. 
The Value of Information (VOI) analysis is reported in full in the Supplementary Appendix. The 
VOI analysis identifies that the parameters causing the greatest decision uncertainty are the 
sensitivity of both tests RT and ST, treatment compliance with ST, the probability of treatment 
success with ST, the probability of infection between tests and treatment compliance with RT. The 
analysis also reports the potential value of reducing uncertainty by data collection within further 




4. Discussion  
This analysis suggests that antenatal syphilis screening with RT incorporating treatment of 
positive women in the same day is a potentially cost-effective strategy. The expected ICER of 
US$298.08 per DALY averted for RT compared to ST is lower than both the WHO recommended 
once per capita GDP (38) and the Woods cost effectiveness threshold values (36), at a threshold 
value of US$ 3,200 per DALY for Brazil. Probabilistic sensitivity analysis (PSA) conducted at 
both 3% and 5% discount rate showed no significant differences in ICER, US$357.44 and 
US$342.29 per DALY, respectively. However, the uncertainty, principally in comparative 
screening test sensitivities and treatment compliance rates, is such that RT screening may still be 
more costly and less effective than ST. 
When we consider the current antenatal screening cost-effectiveness literature, it shows variation 
in the cost-effectiveness estimates; however, those estimates are not directly comparable with our 
findings for a variety of reasons. First, the types of comparators differ from our choice of 
investigation (RT versus VDRL/TPHA test). Some studies focused on comparing different 
combinations of testing and treatment. For instance, the study carried out by Larson and 
colleagues for Zambia considered costs per DALY averted under the assumption of full adherence 
to guidelines (lowest costs) as well as when all positive are treated (slightly higher costs compared 
to full adherence). The highest costs per DALY were observed in scenarios with fewer 
adherences. The variations in cost per DALY were due to the number of DALYs averted in each 
scenario considered (39). The economic implications of scaling up was also considered in some 
studies (40,41). Other studies analyzed syphilis RTs in combination with HIV testing or syphilis 
testing only versus other combinations with HIV tests (42,43).  
One study undertaken in South Africa, a middle-income country, focused on the comparison 
between the combination of RTs and confirmatory TPHA off-site, the current practice at the time 
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versus on-site rapid testing (12). Furthermore, many of the studies are undertaken in countries 
with very different income patterns and congenital syphilis prevalence. Brazil is a middle-income 
country and the majority of studies about the cost-effectiveness of rapid tests for syphilis 
screening were carried out in resource-limited countries in Sub-Saharan Africa and South America 
and Caribbean (11,12). Those studies have estimated costs ranging from US$4 to US$46 per 
DALY averted (32,41,44–47), however, these countries have a higher prevalence of maternal 
syphilis than Brazil.  
The study performed by Owusu-Edusei and colleagues for Sub-Saharan Africa showed that the 
dual-point-of-care test (laboratory-based Rapid Plasma Reagin combined with TPHA) was the 
most promising option in a resource-poor setting, considering a prevalence of 10% infected, with 
the potential to decrease losses to follow-up and reduce overtreatment (48).  
The main limitation of our work is essentially the absence of Brazilian data for some parameters 
needed to populate the model and the assumptions made that could introduce uncertainties. Data 
collection to assess the impact of treatment compliance with ST in Brazil would improve the 
accuracy of estimates. In addition, the prevalence of past infection must be included in more 
elaborated analytical model considering that woman with past infection can trigger treatment and 
follow-up. Parameters causing most of the decision uncertainty such as the sensitivity of RT and 
ST tests must deserve special attention for further research considering the shortage of good 
quality diagnostic accuracy studies. Our analysis uses parameter estimates from a study in a rural 
area, yet higher compliance rates may be expected in urban areas with better access to assistance, 
health education and awareness on prevention. The implication of this is that RT will have better 




Other limitations are related to including only the costs to outpatient activity, thus excluding any 
scenario in which hospitalization would be necessary (other adverse pregnancy events different 
from congenital syphilis). In addition, the model does not include partner tracing and treatment. 
This is due to a lack of evidence concerning the impact of partner tracing on the probability of 
reinfection. Laboratory costs for the standard test (consumables, equipment) also must be 
estimated to include in the total cost of testing. Data collection in further research or 
implementation evaluation should focus on these remaining uncertainties. 
The present work is an important evaluation of ongoing implementation of testing strategies to 
detect and promptly treat maternal syphilis and to prevent syphilis-related birth outcomes in Brazil 
and other low and middle-income countries. Although the sensitivity and specificity of treponemal 
tests and non-treponemal tests vary with the types of tests as well as the stages of syphilis 
infection, the mainstay of diagnosis for syphilis still depends on serologic testing. 
The results from this economic evaluation could help the Brazilian Ministry of Health decision-
makers in setting future directions for the syphilis mother-to-child transmission strategy and 
provide a better understanding of new testing technologies. It become relevant to raise awareness 
among professionals of the benefit of testing by RT in preventing adverse events for the baby and 
improving the training of nurses and technicians in their best use. Furthermore, our findings 
indicate that strategies including RTs for syphilis screening should be reinforced and prioritized in 
local settings and could potentially be extended to other low- and middle-income countries. Even 
other strategies can act in synergy, enhancing the use of rapid testing, such as the congenital 
syphilis elimination campaigns that have been shown to be effective (49) in reducing perinatal 
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Table 1. Parameter values: tests, treatment, status of infection and outcomes 
 
Model Parameters Baseline 
Value 
Range 95% CI 
 
Sources 
Prevalence of Maternal Syphilis 0.012 0.0098 0.0147 (20) 
Tests     
Sensitivity of Rapid Test 0.85 0.73 0.92 (10) 
Specificity of Rapid Test 0.98 0.95 0,99 (10) 
Sensitivity of Standard Test 0.95 0.78 1 (6,23) 
Specificity of Standard Test 0.98 0.98 1 (6) 
Treatment     
Probability of treatment efficacy if administered 
adequately (early or late syphilis) 
0.97 0.94 0.99 (12) 
Probability of compliance full treatment with RT 0.89 0.81 0.95 (12) 
Probability of compliance full treatment with ST 0.61 0.47 0.73 (12) 
Status of Infection     
Probability of remission due to antibiotic therapy 
with penicillin due to other infection different to 
syphilis 
0.001 0 0.005 Expert 
Opinion 
Probability of new infection between tests 
(incidence) 
0.002 0.001 0.004 (23) 
Probability of remain infected after inadequate 
treatment 
0.99 0.99 1 Expert 
Opinion 
Outcomes     
Probability of stillbirth or foetal loss given 
syphilis infected mother 
0.256 0.185 0.342 (18) 
Probability of low birth weight or prematurity 
given syphilis infected mother 
0.131 0.039 0.318 (18) 
Probability of neonatal death given syphilis 
infected mother 
0.123 0.093 0.162 (18) 
Probability of new born with congenital syphilis 
given syphilis infected mother 
0.155 0.075 0.29 (18,35) 
 





Table 2. Model parameters: Costs (US$ international) and QoL values 
 







Costs (US$)     
Rapid Test – ICS 
(test supplies + nurse labour) 
1.29 0.64 1.93 (a) 
Standard Tests - VDRL/TPHA 
(test supplies + technician labour) 
1.21 0.61 1.82 (a) 
VDRL – Follow up (test performed at 
least 3 times) 
(test supplies + technician labour)*3 
1.91 0.95 2.86 (a) 
Expert 
Opinion 
Treatment - B Penicillin G per women 
(1 dose) 
0.26 0.13 0.39 (b) 
Treatment - B Penicillin G per infant 
with CS* 
115.53 57.77 173.30 (b) 
QoL Values  
    
DALY per SB case 10.32 7.10 14.21 (28) 
DALY per LBW case 0.67 0 2.93 (28) 
DALY per ND case 10.32 6.88 14.78 (28) 
DALY per CS case 1.98 0.96 3.71 (28) 
Others 
    
N° of children per birth 1   Expert 
Opinion 
(*)Aqueous crystalline penicillin G, every 8 h for 10 days + daily hospitalization costs 
ICS= Immunochromatographic syphilis test; VDRL= Venereal disease research laboratory test; TPHA= Treponema 
pallidum haemagglutination test. 
QoL= Quality of life; DALY= Disability-Adjusted Life Year. SB= Stillbirth; LBW= Low birth weight; ND= Neonatal 
death; CS= Congenital Syphilis. 
(a) Department of STD, AIDS and Viral Hepatitis from Health Surveillance Secretariat of Ministry of Health. Drug 
Logistics Management and Strategic Inputs (Gerência de Logística de Medicamentos e Insumos Estratégicos – 
GLMIE). 
(b) Health Logistics Department from Ministry of Health (governmental purchasing system) and Table of 
Procedures, Drugs, Orthotics and Prostheses and Special Materials (OPM) of the Unified Health System – SUS 
(management system, SIGTAP). 





Table 3. General model parameters and distributions 
 




(α,β,λ) Rounded Source 
Event probabilities      
Sensitivity of RT 0.85 Beta 45.28 7.99 (10) 
Specificity of RT 0.98 Beta 183.49 3.74 (10) 
Probability of compliance 
treatment with RT 
0.89 Beta 67.42 8.33 (12) 
Sensitivity of ST 0.95 Beta 47.20 2.48 (6,21) 
Specificity of ST 0.98 Beta 736.89 15.04 (6) 
Probability of compliance 
treatment with ST 
0.61 Beta 32.38 20.70 (12) 
Prevalence of disease 0.012 Beta 91.04 7495.52 (19) 
Probability of efficacy of 
treatment 
0.97 Beta 172.52 5.34 (12) 
Probability of remission 
due to antibiotic therapy 
0.001 Beta 0.61 612.41 Expert 
Opinion 
Probability of infection 
between tests (incidence) 
0.002 Beta 6.81 3399.99 (21) 
Probability of remain 
infected due to inadequate 
treatment 
0.99 Beta 1505.02 15.20 Expert 
Opinion 
Probability of stillbirth 0.256 Beta 30.14 87.59 (30) 
Probability of low birth 
weight 
0.131 Beta 2.81 18.66 (30) 
Probability of neonatal 
death 
0.123 Beta 42.70 304.45 (30) 
Probability of congenital 
syphilis 
0.155 Beta 6.59 35.94 (30,37) 
Cost parameters      
Cost of RT 1.29 Gamma 15.36 11.91 (a) 
Cost of ST 1.21 Gamma 15.36 12.67 (a) 
Cost of follow up with 
Non-Treponemal test 
1.91 Gamma 15.35 8.04 (a) 
Assumed 
Cost of treat the mother  0.26 Gamma 15.36 59.54 (b) 
Cost of treat the infant with 
Congenital syphilis 
115.53 Gamma 15.36 0.13 (b) 
HRQoL parameters      
Daly_SBavoid 10.32 Gamma 32.39 0.35 (28) 
Daly_LBWavoid 0.67 Gamma 0.79 0.13 (28) 
Daly_NDavoid 10.32 Gamma 26.25 0.28 (28) 
Daly_CSavoid 1.98 Gamma 7.98 0.45 (28) 
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RT= Rapid test; ST= Standard test; HRQoL= Health related quality of life; DALY= Disability-Adjusted Life Year. 
SB= Stillbirth; LBW= Low birth weight; ND= Neonatal death; CS= Congenital Syphilis. (a) Drug Logistics 
Management and Strategic Inputs (Gerência de Logística de Medicamentos e Insumos Estratégicos – GLMIE) MoH. 
(b) Health Logistics Department and Table of Procedures, Drugs, Orthotics and Prostheses and Special Materials 
(OPM) of MoH (management system, SIGTAP).Cost and HRQoL parameters were applied at a 3% discount rate. 
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Figure 3 
 
 
 
